EWTX Insider Trading Activity and SEC Form 4 Filings
EWTX insider trading summary
Over the past 12 months, insiders at Edgewise Therapeutics, Inc. (EWTX) reported 31 sales worth $19.0M by 6 insiders and 1 open-market purchase worth $199K by 1 insider on SEC Form 4. Net insider selling was $18.8M.
Latest EWTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Joanne M. Donovan | CMO | Sell | $127K (2,919 @ $43.41) |
| Aug 12, 2026 | Kevin Koch | President and CEO | Sell | $40K (913 @ $44.33) |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sell | $14K (304 @ $44.50) |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sell | $95K (2,171 @ $43.79) |
| Aug 12, 2026 | Kevin Koch | President and CEO | Sell | $383K (8,782 @ $43.64) |
| Aug 12, 2026 | Kevin Koch | President and CEO | Sell | $361K (8,276 @ $43.66) |
| Aug 12, 2026 | John R Moore | General Counsel | Sell | $3K (59 @ $44.41) |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sell | $7K (150 @ $44.44) |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sell | $108K (2,475 @ $43.70) |
| Aug 12, 2026 | John R Moore | General Counsel | Sell | $107K (2,439 @ $43.81) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.